Compare FND & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FND | INAB |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 15.6M |
| IPO Year | 2014 | 2020 |
| Metric | FND | INAB |
|---|---|---|
| Price | $51.66 | $1.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 1 |
| Target Price | ★ $73.44 | $6.00 |
| AVG Volume (30 Days) | ★ 3.3M | 60.3K |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.05 | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $4,684,088,000.00 | N/A |
| Revenue This Year | $7.53 | N/A |
| Revenue Next Year | $7.68 | N/A |
| P/E Ratio | $139.15 | ★ N/A |
| Revenue Growth | ★ 5.12 | N/A |
| 52 Week Low | $42.64 | $1.17 |
| 52 Week High | $92.41 | $4.20 |
| Indicator | FND | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 57.66 | 68.74 |
| Support Level | $46.50 | $1.52 |
| Resistance Level | $53.50 | $2.14 |
| Average True Range (ATR) | 2.47 | 0.10 |
| MACD | 0.78 | 0.03 |
| Stochastic Oscillator | 91.08 | 95.85 |
Floor & Decor Holdings Inc operates as a specialty retailer in the hard surface flooring market. Its stores offer a range of tile, wood, laminate, and natural stone flooring products, as well as decorative and installation accessories at everyday low prices. It appeals to a variety of customers including professional installers, commercial businesses, Do It Yourself (DIY) customers, and customers who buy the products for professional installation. Geographically, the group has a presence in the United States region and also offers its product through an e-commerce site. The company segments include retail segment and others.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.